Immunostimulatory effects on B cells by the chemotherapeutic drug Doxorubicin by Kinn, Johan M et al.
POSTER PRESENTATION Open Access
Immunostimulatory effects on B cells by the
chemotherapeutic drug Doxorubicin
Johan M Kinn
*, Ali Zirakzadeh, Jin Hu, Ola Winqvist
From 6th European Workshop on Immune-Mediated Inflammatory Diseases
Nice, France. 23-25 November 2011
Introduction
The efficacy of chemotherapeutic drugs has traditionally
been evaluated by their ability to exhibit a direct cytotoxic
effect on malignant cells. Recently, it has been reported
that certain of these drugs can also enhance the antitumor
efficacy and immunotherapy response through their capa-
city to modulate innate and adaptive immunity [1]. Our
research group has earlier utilized a treatment protocol
based on the principle that tumor reactive T cells can be
isolated from sentinel lymph nodes, expanded in vitro and
then be given back to the patient as an autologous transfu-
sion [2]. B cells are the most abundant APC in lymph
nodes, and it is therefore of interest to study the effects of
chemotherapeutic drugs to B cell antigen presenting
function.
Materials and Methods
Human CD19
+ B cells were preincubated with chemother-
apeutic drugs over night. Next day these cells were used in
the FASCIA assay [3], to evaluate the proliferative
response of autologous CD4
+ T cells. The proliferative
response was analyzed with FACS, by identifying lympho-
blasts as CD3
+/CD4
+/CD45RO
+/HLA-DR
+ cells. Further
analysis of several B-cell surface markers revealed that the
co-stimulatory molecule CD86 was upregulated by some
drugs. The mRNA expression of CD86 and associated reg-
ulatory genes were also analyzed by QT-PCR.
Results
Incubation of B cells with Doxorubicin increased the pro-
liferative response in the functional FASCIA assay, while
several other drugs tested caused suppression. Further
experiments revealed this effect to be due to an increased
expression of the co-stimulatory molecule CD86, and
inhibition experiments with the addition of anti-CD86
antibody reversed the observed finding.
Conclusions
We have demonstrated that Doxorubicin treatment of
human CD19
+ B cells leads to an increased expression of
CD86, and increased antigen presenting function in the
FASCIA assay. Gained knowledge of the immunomodula-
tory properties of chemotherapeutic drugs will permit the
development of drug dose and time schedules which allow
for recovery of immune function, and may possibly lead to
augmented anti-tumor responses.
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